Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. The company was informed by Dr. Wang Shaomeng (Dr. Wang), the company's non-executive director, that on April 2, 2024, he subscribed for a total of 130,000 shares of the company's common shares (shares) on the market. The total cost was about HK$2.3711 million. The average price was approximately HK$18.24 per share, accounting for about 0.045% of the company's total issued share capital on the date of this announcement; and Dr. Yang Dajun (Dr. Yang), the company's executive director and chairman of the board of directors, informed that on April 3, 2024, he acknowledged on the market Purchase a total of 100,000 shares The total cost of shares is approximately HK$1,794,600, and the average price is approximately HK$17.95 per share, accounting for approximately 0.034% of the total issued share capital of the Company as of the date of this announcement.
As of the date of this announcement, according to section XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, Dr Wong and Dr Yeung are each deemed to have an interest in a total of 64.5859 million shares through controlled corporate interests, shared interests with other parties, spousal rights, and as full trust clients (for further details, please refer to the section “The interests and underpositions of directors and top executives in the shares and related shares of the Company or its associated corporations” for the six months ended June 30, 2023). Therefore, after the subscription is completed, Dr. Wang and Dr. Yang will each be deemed to have interests in a total of 648.15,900 shares, accounting for approximately 22.33% of the company's total issued share capital at the date of this announcement.
According to Dr. Wang and Dr. Yang, the subscription matters indicate their confidence in the company's future.